- Home
- NCPL vs IXHL Comparison
NCPL vs IXHL Comparison
Compare NCPL & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- IXHL
- Stock Information
- Founded
- NCPL 1984
- IXHL 2001
- Country
- NCPL United States
- IXHL Australia
- Employees
- NCPL N/A
- IXHL N/A
- Industry
- NCPL Investment Managers
- IXHL
- Sector
- NCPL Finance
- IXHL
- Exchange
- NCPL Nasdaq
- IXHL Nasdaq
- Market Cap
- NCPL 4.3M
- IXHL 3.6M
- IPO Year
- NCPL N/A
- IXHL N/A
- Fundamental
- Price
- NCPL $2.70
- IXHL $0.20
- Analyst Decision
- NCPL
- IXHL
- Analyst Count
- NCPL 0
- IXHL 0
- Target Price
- NCPL N/A
- IXHL N/A
- AVG Volume (30 Days)
- NCPL 166.3K
- IXHL 144.2M
- Earning Date
- NCPL 07-28-2025
- IXHL 05-15-2025
- Dividend Yield
- NCPL N/A
- IXHL N/A
- EPS Growth
- NCPL N/A
- IXHL N/A
- EPS
- NCPL N/A
- IXHL N/A
- Revenue
- NCPL $812,612.00
- IXHL $98,000.00
- Revenue This Year
- NCPL N/A
- IXHL $3,817.06
- Revenue Next Year
- NCPL $101.16
- IXHL $66.67
- P/E Ratio
- NCPL N/A
- IXHL N/A
- Revenue Growth
- NCPL N/A
- IXHL N/A
- 52 Week Low
- NCPL $1.41
- IXHL $0.08
- 52 Week High
- NCPL $11.90
- IXHL $3.55
- Technical
- Relative Strength Index (RSI)
- NCPL 76.49
- IXHL 43.86
- Support Level
- NCPL $1.75
- IXHL $0.19
- Resistance Level
- NCPL $2.19
- IXHL $0.31
- Average True Range (ATR)
- NCPL 0.21
- IXHL 0.14
- MACD
- NCPL 0.07
- IXHL 0.02
- Stochastic Oscillator
- NCPL 84.85
- IXHL 11.91
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.